2013
DOI: 10.1111/head.12211
|View full text |Cite
|
Sign up to set email alerts
|

SumaRT/Nap vs Naproxen Sodium in Treatment and Disease Modification of Migraine: A Pilot Study

Abstract: Naproxen sodium, when used as a sole acute treatment early in attacks, appears to reduce the frequency of headache days and migraine attacks for a select number of subjects over a 3-month period. SumaRT/Nap is more effective at 2-hour headache reduction than naproxen sodium alone, but has less impact on reducing attack frequency or the number of headache days. Both treatments were well tolerated, and there was no convincing evidence that either medication led to MOH.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
8
0

Year Published

2014
2014
2016
2016

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 22 publications
0
8
0
Order By: Relevance
“…Additionally, there is a clear clinical need to have alternative treatments for acute intervention that do not put CM patients at risk for MOH or at the very least can be used in conjunction with other acute drug interventions to reduce exposure to medications associated with MOH. Both clinical trials and epidemiological studies suggest that most CM patients use acute medication at frequencies above those defined as MO by ICHD‐III beta . Although repeated exposure to bupivacaine has to date not been associated with MOH, further studies will be required before this can be stated conclusively.…”
Section: Discussionmentioning
confidence: 99%
“…Additionally, there is a clear clinical need to have alternative treatments for acute intervention that do not put CM patients at risk for MOH or at the very least can be used in conjunction with other acute drug interventions to reduce exposure to medications associated with MOH. Both clinical trials and epidemiological studies suggest that most CM patients use acute medication at frequencies above those defined as MO by ICHD‐III beta . Although repeated exposure to bupivacaine has to date not been associated with MOH, further studies will be required before this can be stated conclusively.…”
Section: Discussionmentioning
confidence: 99%
“…A single small pilot study suggested a reduction of migraine frequency over baseline at 3 months for naproxen when used daily for 1 month, and as the sole abortive for the subsequent 2 months. 102 Parenteral formulations of ketorolac are available as an intramuscular injection and nasal spray. 103,104 Ketorolac is widely used as an acute treatment for migraine, especially parenterally.…”
Section: Adverse Events and Contraindicationsmentioning
confidence: 99%
“…On behalf of my coauthors, I am delighted to accept the inaugural Headache Members'. Choice Award for our manuscript, “Trigger Point Injections for Headache Disorders: Expert Consensus Methodology and Narrative Review.” It was an honor for our work to be nominated among rigorous, innovative studies in basic and clinical science, which were all deserving of such recognition.…”
mentioning
confidence: 99%